| Immune checkpoint therapy—current perspectives and future directions P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui, P Singh, ... Cell 186 (8), 1652-1669, 2023 | 439 | 2023 |
| Cutting edge: Piezo1 mechanosensors optimize human T cell activation CSC Liu, D Raychaudhuri, B Paul, Y Chakrabarty, AR Ghosh, ... The Journal of Immunology 200 (4), 1255-1260, 2018 | 151 | 2018 |
| Myeloid cell-targeted therapies for solid tumours S Goswami, S Anandhan, D Raychaudhuri, P Sharma Nature Reviews Immunology 23 (2), 106-120, 2023 | 137 | 2023 |
| Lactate induces pro-tumor reprogramming in intratumoral plasmacytoid dendritic cells D Raychaudhuri, R Bhattacharya, BP Sinha, CSC Liu, AR Ghosh, ... Frontiers in immunology 10, 1878, 2019 | 137 | 2019 |
| Adipose recruitment and activation of plasmacytoid dendritic cells fuel metaflammation AR Ghosh, R Bhattacharya, S Bhattacharya, T Nargis, O Rahaman, ... Diabetes 65 (11), 3440-3452, 2016 | 108 | 2016 |
| A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19 Y Ray, SR Paul, P Bandopadhyay, R D’Rozario, J Sarif, D Raychaudhuri, ... Nature Communications 13 (1), 383, 2022 | 36 | 2022 |
| A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist A Mukherjee, D Raychaudhuri, BP Sinha, B Kundu, M Mitra, B Paul, ... Journal of Medicinal Chemistry 63 (9), 4776-4789, 2020 | 24 | 2020 |
| Cutting edge: dysregulated endocannabinoid-rheostat for plasmacytoid dendritic cell activation in a systemic lupus endophenotype O Rahaman, R Bhattacharya, CSC Liu, D Raychaudhuri, AR Ghosh, ... The Journal of Immunology 202 (6), 1674-1679, 2019 | 19 | 2019 |
| Activity-guided development of potent and selective toll-like receptor 9 antagonists B Paul, O Rahaman, S Roy, S Pal, S Satish, A Mukherjee, AR Ghosh, ... European Journal of Medicinal Chemistry 159, 187-205, 2018 | 19 | 2018 |
| Systematic optimization of potent and orally bioavailable purine scaffold as a dual inhibitor of toll-like receptors 7 and 9 B Kundu, D Raychaudhuri, A Mukherjee, BP Sinha, D Sarkar, ... Journal of Medicinal Chemistry 64 (13), 9279-9301, 2021 | 18 | 2021 |
| Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockade S Goswami, D Raychaudhuri, P Singh, SM Natarajan, Y Chen, C Poon, ... Nature Cancer 4 (10), 1455-1473, 2023 | 17 | 2023 |
| Plasma gradient of soluble urokinase-type plasminogen activator receptor is linked to pathogenic plasma proteome and immune transcriptome and stratifies outcomes in severe COVID-19 J Sarif, D Raychaudhuri, R D’Rozario, P Bandopadhyay, P Singh, ... Frontiers in Immunology 12, 738093, 2021 | 17 | 2021 |
| Histone lactylation drives CD8+ T cell metabolism and function D Raychaudhuri, P Singh, B Chakraborty, M Hennessey, AJ Tannir, ... Nature immunology 25 (11), 2140-2151, 2024 | 9 | 2024 |
| Circulating interleukin-8 dynamics parallels disease course and is linked to clinical outcomes in severe COVID-19 R D’Rozario, D Raychaudhuri, P Bandopadhyay, J Sarif, P Mehta, ... Viruses 15 (2), 549, 2023 | 7 | 2023 |
| Role of Ca2+ in toll-like receptor 9 activation in human plasmacytoid dendritic cells D Raychaudhuri, P Duttagupta, CSC Liu, J Sarif, AR Ghosh, O Rahaman, ... Cytokine 125, 154822, 2020 | 5 | 2020 |
| Clinical trial subgroup analyses to investigate clinical and immunological outcomes of convalescent plasma therapy in severe COVID-19 D Raychaudhuri, P Bandopadhyay, R D’Rozario, J Sarif, Y Ray, SR Paul, ... Mayo Clinic Proceedings: Innovations, Quality & Outcomes 6 (6), 511-524, 2022 | 4 | 2022 |
| 575 Epigenetic modulation by KDM6B in myeloid cells regulates glioblastoma immune checkpoint therapy outcomes P Singh, D Raychaudhuri, Y Chen, C Poon, M Hennessey, A Tannir, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| Cutting Edge: ATP13A2 Is an Endolysosomal Regulator of TLR9/7 Activation in Human Plasmacytoid Dendritic Cells P Bandopadhyay, J Sarif, R D’Rozario, CSC Liu, BP Sinha, MA Hoque, ... The Journal of Immunology 213 (2), 109-114, 2024 | | 2024 |
| Loss of KDM6A-mediated genomic instability and metabolic reprogramming differentially regulates responses to immune checkpoint therapy and chemotherapy in bladder cancer. P Singh, D Raychaudhuri, B Chakraborty, S Meher, AJ Tannir, ... bioRxiv, 2024.10. 31.621396, 2024 | | 2024 |
| Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. Viruses 2023, 15, 549 R D’Rozario, D Raychaudhuri, P Bandopadhyay, J Sarif, P Mehta, ... | | 2023 |
